-
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
•
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease in turnover at constant exchange rates (CER) to CHF 15.3 billion (USD 17.2 billion) in its Q1 2023 report. The decline was attributed to the appreciation of the Swiss franc and a predicted drop in…
-
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center, randomized, open, positive-controlled Phase III RENOTORCH study has reached pre-set endpoints at the interim analysis stage. The study evaluates the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with axitinib for the treatment of moderate to…
-
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical study for birociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has successfully reached the primary endpoint in patients with HR+/HER2- advanced breast cancer that has progressed after previous endocrine therapy combined with fulvestrant. Positive Mid-Term Analysis…
-
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
•
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ, NASDAQ: AZN) and the state-backed Future Industry Investment Fund in October 2017, has announced plans to raise RMB 2.6 billion (USD 376.1 million) through a private placement of 40,815,137 shares. The funds raised will be…
-
LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product
•
Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with South Korea-headquartered LegoChem Biosciences, Inc. Under this agreement, the two companies will leverage LaNova’s antibody assets and LCB’s antibody-drug conjugate (ADC) technology platform to develop an innovative ADC product. LaNova Medicines: A Clinical-Stage R&D CompanyEstablished…
-
Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs
•
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced plans to enter into an exclusive licensing agreement with Shenyang 3SBio Co., Ltd. The deal grants 3SBio extensive rights, including development, regulatory, manufacturing, use, sales, export, and import, for its antitumor programs 602, 609, 705,…
-
Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech
•
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Autobio Diagnostics Co., Ltd (SHA: 603658). The funds raised will be directed towards technology research and development, product iteration, and end-implementation efforts. Company Background…
-
Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million
•
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire an 87.5% stake in US-based liquid embolic agent specialist BlackSwan Vascular Inc., for USD 37.5 million. This strategic move signifies Grand Pharma’s commitment to expanding its global presence in the medical device industry. BlackSwan Vascular…
-
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 product candidate, ZG2001. ZG2001 is an in-house discovered oral pan-KRAS mutation inhibitor under development for the treatment of KRAS mutant tumors. Prevalence…
-
Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct two clinical studies. One study will investigate the combination of its drug candidate BL-B01D1 with osimertinib (Tagrisso) for the treatment of locally advanced or metastatic non-small…
-
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
•
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic…
-
Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its small-molecule HER2 inhibitor, pyrotinib. The drug is now approved for use in combination with Herceptin (trastuzumab) plus chemotherapy to treat recurrent or metastatic breast cancer…
-
Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
•
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a Phase I/II clinical study for its antibody-drug conjugate (ADC), XNW27011. The study will focus on locally advanced unresectable or metastatic malignant solid tumors expressing Claudin 18.2 (CLDN18.2).…
-
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
-
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
•
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of primary intracranial malignant tumors. TRPML1 Inhibitor’s Non-Clinical Study ResultsNon-clinical studies have demonstrated that the TRPML1 inhibitor, Y-1, can effectively inhibit…
-
AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
•
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded, highlighting the latest trends in clinical cancer research. The event featured a range of CAR-T cell therapies under development, including Allogene Therapeutics’ (NASDAQ: ALLO) CD70-targeting allogeneic treatment ALLO-316, as well as anti-CD19/CD20 and anti-TACI/BCMA bispecific…
-
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the global RATIONALE 305 trial has successfully met its primary endpoint of overall survival. The trial demonstrated that tislelizumab, in combination with chemotherapy, showed superior overall survival (OS) compared to chemotherapy alone in patients with advanced…
-
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III Neotorch study for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Plenary Series this…
-
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC), SYS6010, which is intended for the treatment of advanced solid tumors. Pre-Clinical Studies and Patent Protection for SYS6010Pre-clinical studies have demonstrated that…
-
Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results
•
Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed by industry media to the recent leak of positive data from the ongoing Phase III CARTITUDE-4 study. The study is assessing Legend’s BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Carvykti (ciltacabtagene autoleucel), as a…
